
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health demonstrates strong growth prospects, with a year-over-year revenue increase of 7% despite challenging comparisons, underscoring its innovation in data offerings and strategic partnerships with electronic medical records. The company maintains a leading position in the circulating genomic profiling liquid biopsy market, holding over 50% market share, and has achieved nearly 30% year-over-year growth since its inception in 2014. Additionally, recent advancements in reimbursement coverage for its Reveal and Shield tests suggest a promising trajectory for average selling price expansion and volume growth, further enhancing the company's financial outlook.
Bears say
The analysis of Guardant Health's financial outlook reveals significant concerns regarding reimbursement dynamics that may negatively impact average selling prices (ASP) and overall profitability. Notably, the potential implementation of PAMA regulations could result in a one-time revenue decline of approximately $100 million, further complicating the financial landscape for the company. Additionally, uncertainties in the regulatory environment for multi-cancer early detection (MCED) tests pose risks to adoption rates, potentially hindering the company's growth trajectory and financial performance.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares